ANTENGENE-B Shares Surge Over 11% Following $1.2 Billion Licensing Agreement with UCB

Stock News

Mar 05

ANTENGENE-B (06996) rose more than 11%, extending gains after closing nearly 10% higher in the previous session. At the time of writing, the stock was up 11.71% to HK$3.53, with a turnover of HK$7.15 million. The increase follows the announcement that ANTENGENE has entered into an agreement with UCB, granting the latter exclusive global rights to develop, manufacture, and commercialize the CD19/CD3 bispecific T-cell engager ATG-201, including related production technology licenses. ANTENGENE will receive a total of $80 million, consisting of a $60 million upfront payment and an additional $20 million in near-term milestone payments. The company is also eligible for up to $1.1 billion in future milestone payments and tiered royalties based on net sales.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1163251772"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1163251772\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1163251772?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 10:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163251772","market":"hk","top_or_hot":-1,"title":"ANTENGENE-B Shares Surge Over 11% Following $1.2 Billion Licensing Agreement with UCB","media":"Stock News","content":"<p>ANTENGENE-B (06996) rose more than 11%, extending gains after closing nearly 10% higher in the previous session. At the time of writing, the stock was up 11.71% to HK$3.53, with a turnover of HK$7.15 million. The increase follows the announcement that ANTENGENE has entered into an agreement with UCB, granting the latter exclusive global rights to develop, manufacture, and commercialize the CD19/CD3 bispecific T-cell engager ATG-201, including related production technology licenses. ANTENGENE will receive a total of $80 million, consisting of a $60 million upfront payment and an additional $20 million in near-term milestone payments. The company is also eligible for up to $1.1 billion in future milestone payments and tiered royalties based on net sales.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ANTENGENE-B Shares Surge Over 11% Following $1.2 Billion Licensing Agreement with UCB</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nANTENGENE-B Shares Surge Over 11% Following $1.2 Billion Licensing Agreement with UCB\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-05 10:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ANTENGENE-B (06996) rose more than 11%, extending gains after closing nearly 10% higher in the previous session. At the time of writing, the stock was up 11.71% to HK$3.53, with a turnover of HK$7.15 million. The increase follows the announcement that ANTENGENE has entered into an agreement with UCB, granting the latter exclusive global rights to develop, manufacture, and commercialize the CD19/CD3 bispecific T-cell engager ATG-201, including related production technology licenses. ANTENGENE will receive a total of $80 million, consisting of a $60 million upfront payment and an additional $20 million in near-term milestone payments. The company is also eligible for up to $1.1 billion in future milestone payments and tiered royalties based on net sales.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1163251772","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163251772","pubTimestamp":1772678537,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ANTENGENE-B (06996) rose more than 11%, extending gains after closing nearly 10% higher in the previous session. At the time of writing, the stock was up 11.71% to HK$3.53, with a turnover of HK$7.15...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","BK4585":"ETF&股票定投概念","VT":"世界全股市ETF-Vanguard","BK1583":"高瓴概念","06996":"德琪医药-B","VXUS":"国际股票ETF-Vanguard","BK4588":"碎股","BK1191":"制药"},"translate_title":"与UCB达成12亿美元许可协议后，德琪-B股价飙升逾11%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VT":1,"VXUS":1,"06996":1},"content_text":"ANTENGENE-B (06996) rose more than 11%, extending gains after closing nearly 10% higher in the previous session. At the time of writing, the stock was up 11.71% to HK$3.53, with a turnover of HK$7.15 million. The increase follows the announcement that ANTENGENE has entered into an agreement with UCB, granting the latter exclusive global rights to develop, manufacture, and commercialize the CD19/CD3 bispecific T-cell engager ATG-201, including related production technology licenses. ANTENGENE will receive a total of $80 million, consisting of a $60 million upfront payment and an additional $20 million in near-term milestone payments. The company is also eligible for up to $1.1 billion in future milestone payments and tiered royalties based on net sales.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}